Erratum to ‘Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis’ [Eur J Cancer 149 (2021) 134–152] (European Journal of Cancer (2021) 149 (134–152), (S095980492100143X), (10.1016/j.ejca.2021.02.035))

Francesco Schettini, Fabiola Giudici, Ottavia Bernocchi, Marianna Sirico, Silvia P. Corona, Mario Giuliano, Mariavittoria Locci, Ida Paris, Giovanni Scambia, Sabino De Placido, Pasquale Rescigno, Aleix Prat, Giuseppe Curigliano, Daniele Generali

Research output: Contribution to journalComment/debatepeer-review

Abstract

The publisher regrets that errors were made regarding the named trial PRIMA in section 4.4. ‘Results based on mutational status’. The sentence “Intriguingly, the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) trial in ovarian cancer was able to identify a PFS improvement with niraparib monotherapy in HRR-proficient MOC [31].” should have appeared as follows “Intriguingly, the PRIMA trial in ovarian cancer was able to identify a PFS improvement with niraparib monotherapy in HRR-proficient MOC [31].” The publisher would like to apologise for any inconvenience caused.

Original languageEnglish
Pages (from-to)274
Number of pages1
JournalEuropean Journal of Cancer
Volume153
DOIs
Publication statusPublished - Aug 2021

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Erratum to ‘Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis’ [Eur J Cancer 149 (2021) 134–152] (European Journal of Cancer (2021) 149 (134–152), (S095980492100143X), (10.1016/j.ejca.2021.02.035))'. Together they form a unique fingerprint.

Cite this